117 related articles for article (PubMed ID: 38676689)
21. Blood biomarkers with Parkinson's disease clusters and prognosis: The oxford discovery cohort.
Lawton M; Baig F; Toulson G; Morovat A; Evetts SG; Ben-Shlomo Y; Hu MT
Mov Disord; 2020 Feb; 35(2):279-287. PubMed ID: 31693246
[TBL] [Abstract][Full Text] [Related]
22. Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: A systematic review and meta-analysis.
Rahmani F; Saghazadeh A; Rahmani M; Teixeira AL; Rezaei N; Aghamollaii V; Ardebili HE
Brain Res; 2019 Feb; 1704():127-136. PubMed ID: 30296429
[TBL] [Abstract][Full Text] [Related]
23. Relationship of circulatory BDNF with cognitive deficits in people with Parkinson's disease.
Khalil H; Alomari MA; Khabour OF; Al-Hieshan A; Bajwa JA
J Neurol Sci; 2016 Mar; 362():217-20. PubMed ID: 26944151
[TBL] [Abstract][Full Text] [Related]
24. Decreased serum BDNF contributes to the onset of REM sleep behavior disorder in Parkinson's disease patients.
Jin H; Shen H; Liu C; Wang L; Mao C; Chen J; Liu CF; Zhang Y
Neurosci Lett; 2023 Aug; 812():137380. PubMed ID: 37423466
[TBL] [Abstract][Full Text] [Related]
25. Postural instability and gait are associated with severity and prognosis of Parkinson disease.
van der Heeden JF; Marinus J; Martinez-Martin P; Rodriguez-Blazquez C; Geraedts VJ; van Hilten JJ
Neurology; 2016 Jun; 86(24):2243-50. PubMed ID: 27178702
[TBL] [Abstract][Full Text] [Related]
26. BDNF levels and nigrostriatal degeneration in "drug naïve" Parkinson's disease patients. An "in vivo" study using I-123-FP-CIT SPECT.
Hernández-Vara J; Sáez-Francàs N; Lorenzo-Bosquet C; Corominas-Roso M; Cuberas-Borròs G; Lucas-Del Pozo S; Carter S; Armengol-Bellapart M; Castell-Conesa J
Parkinsonism Relat Disord; 2020 Sep; 78():31-35. PubMed ID: 32682292
[TBL] [Abstract][Full Text] [Related]
27. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Smith KM; Eyal E; Weintraub D;
JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
[TBL] [Abstract][Full Text] [Related]
28. Correlation among olfactory function, motors' symptoms, cognitive impairment, apathy, and fatigue in patients with Parkinson's disease.
Masala C; Solla P; Liscia A; Defazio G; Saba L; Cannas A; Cavazzana A; Hummel T; Haehner A
J Neurol; 2018 Aug; 265(8):1764-1771. PubMed ID: 29804147
[TBL] [Abstract][Full Text] [Related]
29. Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS.
Goldman JG; Stebbins GT; Leung V; Tilley BC; Goetz CG
Parkinsonism Relat Disord; 2014 Nov; 20(11):1135-9. PubMed ID: 25150770
[TBL] [Abstract][Full Text] [Related]
30. What determines resilience in patients with Parkinson's disease?
Robottom BJ; Gruber-Baldini AL; Anderson KE; Reich SG; Fishman PS; Weiner WJ; Shulman LM
Parkinsonism Relat Disord; 2012 Feb; 18(2):174-7. PubMed ID: 21975263
[TBL] [Abstract][Full Text] [Related]
31. The effects of motor rehabilitation training on clinical symptoms and serum BDNF levels in Parkinson's disease subjects.
Angelucci F; Piermaria J; Gelfo F; Shofany J; Tramontano M; Fiore M; Caltagirone C; Peppe A
Can J Physiol Pharmacol; 2016 Apr; 94(4):455-61. PubMed ID: 26863448
[TBL] [Abstract][Full Text] [Related]
32. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients.
Huang S; Zhao Z; Ma J; Hu S; Li L; Wang Z; Sun W; Shi X; Li M; Zheng J
Neurosci Lett; 2021 Jan; 741():135480. PubMed ID: 33161104
[TBL] [Abstract][Full Text] [Related]
33. Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum.
Lindqvist D; Kaufman E; Brundin L; Hall S; Surova Y; Hansson O
PLoS One; 2012; 7(10):e47387. PubMed ID: 23082161
[TBL] [Abstract][Full Text] [Related]
34. Cognitive impairment and BDNF serum levels.
Siuda J; Patalong-Ogiewa M; Żmuda W; Targosz-Gajniak M; Niewiadomska E; Matuszek I; Jędrzejowska-Szypułka H; Lewin-Kowalik J; Rudzińska-Bar M
Neurol Neurochir Pol; 2017; 51(1):24-32. PubMed ID: 28341039
[TBL] [Abstract][Full Text] [Related]
35. Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms.
Tong Q; Zhang L; Yuan Y; Jiang S; Zhang R; Xu Q; Ding J; Li D; Zhou X; Zhang K
Parkinsonism Relat Disord; 2015 Aug; 21(8):882-7. PubMed ID: 26028271
[TBL] [Abstract][Full Text] [Related]
36. Autonomic Symptoms Correlate with Non-Autonomic Non-Motor Symptoms and Sleep Problems in Patients with Parkinson's Disease.
Matsubara T; Suzuki K; Fujita H; Watanabe Y; Sakuramoto H; Matsubara M; Hirata K
Eur Neurol; 2018; 80(3-4):193-199. PubMed ID: 30572329
[TBL] [Abstract][Full Text] [Related]
37. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
[TBL] [Abstract][Full Text] [Related]
38. Predictors of fatigue severity in early, de novo Parkinson disease patients: A 1-year longitudinal study.
Siciliano M; Trojano L; De Micco R; Giordano A; Russo A; Tedeschi G; Chiorri C; Tessitore A
Parkinsonism Relat Disord; 2020 Oct; 79():3-8. PubMed ID: 32853825
[TBL] [Abstract][Full Text] [Related]
39. Hyposmia as a marker of (non-)motor disease severity in Parkinson's disease.
Roos DS; Twisk JWR; Raijmakers PGHM; Doty RL; Berendse HW
J Neural Transm (Vienna); 2019 Nov; 126(11):1471-1478. PubMed ID: 31515655
[TBL] [Abstract][Full Text] [Related]
40. Apathy in Parkinson's disease with REM sleep behavior disorder.
Bargiotas P; Ntafouli M; Lachenmayer ML; Krack P; Schüpbach WMM; Bassetti CLA
J Neurol Sci; 2019 Apr; 399():194-198. PubMed ID: 30826716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
